Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
GURDP
MCID: GST106
MIFTS: 64

Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets (GURDP)

Categories: Blood diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Gastrointestinal Ulceration, Recurrent, with Dysfunctional...

About this section

MalaCards integrated aliases for Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets:

Name: Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets 56 73 29 6 17
Gurdp 56 73
Cytosolic Phospholipase-A2 Alpha Deficiency Associated Bleeding Disorder 58
Platelet Dysfunction Due to Cytosolic Phospholipase-A2 Alpha Deficiency 58
Phospholipase A2, Group Iva, Deficiency of 56
Deficiency of Phospholipase A2, Group Iva 73
Pla2g4a-Related Platelet Dysfunction 58
Ulcer 43

Characteristics:

OMIM:

56
Inheritance:
autosomal recessive

Miscellaneous:
onset in first years of life


HPO:

31
gastrointestinal ulceration, recurrent, with dysfunctional platelets:
Inheritance autosomal recessive inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Gastrointestinal diseases Blood diseases
See all MalaCards categories (disease lists)
Orphanet: 58  
Rare gastroenterological diseases
Rare haematological diseases


Sources

Summaries for Gastrointestinal Ulceration, Recurrent, with Dysfunctional...

About this section
OMIM : 56 Recurrent gastrointestinal ulceration with dysfunctional platelets (GURDP) is an autosomal recessive disorder characterized by onset of severe gastrointestinal mucosal ulceration in early childhood. Affected individuals may have secondary iron deficiency anemia or malnourishment. Studies of platelet aggregation show a functional defect associated with decreased thromboxane-A2 production and decreased eicosanoid biosynthesis. The gastrointestinal disease is believed to result from decreased or absent production of prostaglandins that protect the gut mucosa (summary by Adler et al., 2008 and Faioni et al., 2014). (618372)

MalaCards based summary : Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets, also known as gurdp, is related to decubitus ulcer and peptic ulcer perforation. An important gene associated with Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets is PLA2G4A (Phospholipase A2 Group IVA), and among its related pathways/superpathways are Phospholipase-C Pathway and p70S6K Signaling. The drugs Acetylcysteine and Acyclovir have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and colon, and related phenotypes are gastric ulcer and duodenal ulcer

UniProtKB/Swiss-Prot : 73 Gastrointestinal ulceration, recurrent, with dysfunctional platelets: An autosomal recessive disorder characterized by recurrent gastrointestinal mucosal ulcers, gastrointestinal bleeding, chronic anemia, iron deficiency, and abdominal pain. Disease features also include platelet dysfunction, and globally decreased eicosanoid synthesis.

Sources

Related Diseases for Gastrointestinal Ulceration, Recurrent, with Dysfunctional...

About this section

Diseases related to Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2495)
# Related Disease Score Top Affiliating Genes
1 decubitus ulcer 33.6 PDGFB FGF2
2 peptic ulcer perforation 33.5 S100A8 HRH2 GAST
3 duodenal ulcer 33.4 S100A8 HRH2 GAST EGF
4 active peptic ulcer disease 33.1 PTGS2 PTGS1 HRH2
5 peptic ulcer disease 33.1 S100A8 PTGS2 PTGS1 HRH2 GAST
6 chronic ulcer of skin 32.9 PDGFB FGF2 EGF
7 helicobacter pylori infection 32.4 S100A8 GAST
8 zollinger-ellison syndrome 32.2 HRH2 GAST EGF
9 gastric ulcer 31.3 S100A8 PTGS2 PTGS1 HRH2 GAST FGF2
10 gastritis 31.2 S100A8 PTGS2 PTGS1 HRH2 GAST
11 duodenitis 31.2 S100A8 GAST
12 gastroduodenitis 30.9 S100A8 GAST
13 hernia, hiatus 30.8 HRH2 GAST
14 inflammatory bowel disease 30.6 S100A8 PTGS2 PTGS1 FGF2 EGF
15 stomach disease 30.6 S100A8 PTGS2 PTGS1 HRH2 GAST
16 microinvasive gastric cancer 30.5 S100A8 GAST
17 esophagitis 30.3 PTGS2 HRH2 GAST EGF
18 bile reflux 30.2 S100A8 PTGS2 GAST
19 peptic esophagitis 30.2 S100A8 PTGS2 HRH2 GAST
20 constipation 30.0 PTGS2 PTGS1 GAST
21 atrophic gastritis 30.0 S100A8 PTGS2 GAST EGF
22 gastric cancer 29.9 S100A8 PTGS2 HRH2 GAST FGF2 EGF
23 urticaria 29.8 PTGS2 PTGS1 HRH2
24 laryngitis 29.8 HRH2 FGF2
25 squamous cell carcinoma, head and neck 29.7 PTGS2 PTGS1 FGF2 EGF
26 gastric adenocarcinoma 29.4 S100A8 PTGS2 GAST EGF
27 duodenal gastrinoma 29.3 HRH2 GAST
28 hydrops, lactic acidosis, and sideroblastic anemia 29.2 PTGS2 PTGS1
29 duodenum disease 29.2 S100A8 GAST
30 aspirin resistance 29.1 PTGS2 PTGS1
31 dry eye syndrome 29.0 S100A8 FGF2 EGF
32 autoimmune gastritis 28.9 GAST EGF
33 gastroesophageal reflux 28.8 S100A8 PTGS2 PTGS1 HRH2 GAST EGF
34 glioma 28.0 PDGFB FGF2 EGF
35 pancreatic adenocarcinoma 27.5 PTGS2 PDGFB GAST FGF2 EGF
36 medulloblastoma 27.4 PTGS2 PDGFB FGF2 EGF
37 ulcerative colitis 12.9
38 buruli ulcer 12.7
39 ulcer of lower limbs 12.7
40 corneal ulcer 12.7
41 gastrojejunal ulcer 12.6
42 necrotizing ulcerative gingivitis 12.6
43 ulcerative proctitis 12.6
44 mooren's ulcer 12.5
45 umbilical cord ulceration and intestinal atresia 12.5
46 ulceration of vulva 12.5
47 mucocutaneous ulceration, chronic 12.5
48 central corneal ulcer 12.5
49 perforated corneal ulcer 12.4
50 marginal corneal ulcer 12.4

Graphical network of the top 20 diseases related to Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets:



Diseases related to Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets
Sources

Symptoms & Phenotypes for Gastrointestinal Ulceration, Recurrent, with Dysfunctional...

About this section

Human phenotypes related to Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets:

31 (show all 7)
# Description HPO Frequency HPO Source Accession
1 gastric ulcer 31 HP:0002592
2 duodenal ulcer 31 HP:0002588
3 iron deficiency anemia 31 HP:0001891
4 esophageal ulceration 31 HP:0004791
5 impaired platelet aggregation 31 HP:0003540
6 decreased serum thromboxane b2 31 HP:0032244
7 decreased circulating 12-hete 31 HP:0032575

Symptoms via clinical synopsis from OMIM:

56
Abdomen Gastrointestinal:
fistulas
mucosal ulceration, recurrent
duodenal ulcers
small bowel ulcers
esophageal ulcers

Laboratory Abnormalities:
decreased serum eicosanoids
decreased thromboxane-b2 (txb2)
decreased 12-hete

Hematology:
impaired platelet aggregation due to impaired thromboxane-a2 production
iron deficiency anemia, secondary

Clinical features from OMIM:

618372

MGI Mouse Phenotypes related to Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.8 EGF GAST HRH2 PLA2G4A PTGS1 PTGS2
2 endocrine/exocrine gland MP:0005379 9.73 EGF GAST HRH2 PLA2G4A PTGS1 PTGS2
3 muscle MP:0005369 9.55 FGF2 PDGFB PLA2G4A PTGS1 PTGS2
4 neoplasm MP:0002006 9.35 FGF2 GAST PLA2G4A PTGS1 PTGS2
5 reproductive system MP:0005389 9.1 EGF FGF2 PDGFB PLA2G4A PTGS1 PTGS2
Sources

Drugs & Therapeutics for Gastrointestinal Ulceration, Recurrent, with Dysfunctional...

About this section

Drugs for Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 729)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Acyclovir Approved Phase 4 59277-89-3 2022
3
Saxagliptin Approved Phase 4 361442-04-8 11243969
4
Insulin aspart Approved Phase 4 116094-23-6 16132418
5
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
6
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
7
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
8
Enalaprilat Approved Phase 4 76420-72-9 6917719
9
Docosanol Approved, Investigational Phase 4 661-19-8, 30303-65-2 12620
10
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
11
Ondansetron Approved Phase 4 99614-02-5 4595
12
Capsaicin Approved Phase 4 404-86-4 1548943
13
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
14
Sulpiride Approved, Investigational Phase 4 15676-16-1 5355
15
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
16 Bemiparin Approved, Investigational Phase 4 91449-79-5
17
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
18
Ibuprofen Approved Phase 4 15687-27-1 3672
19
Atorvastatin Approved Phase 4 134523-00-5 60823
20
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
21
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
22
Metformin Approved Phase 4 657-24-9 14219 4091
23
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
24
Acetaminophen Approved Phase 4 103-90-2 1983
25
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
26
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
27
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
28
Mercaptopurine Approved Phase 4 50-44-2 667490
29
Sucralfate Approved Phase 4 54182-58-0
30
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
31
Phylloquinone Approved, Investigational Phase 4 84-80-0
32
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
33
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 54677470 5281106
34
Remifentanil Approved Phase 4 132875-61-7 60815
35
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
36
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
37
Ticagrelor Approved Phase 4 274693-27-5 9871419
38
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
39
Bisoprolol Approved Phase 4 66722-44-9 2405
40
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
41
Misoprostol Approved Phase 4 59122-46-2 5282381
42
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
43
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
44
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
45
Infliximab Approved Phase 4 170277-31-3
46
Nicotine Approved Phase 4 54-11-5 942 89594
47
Magnesium citrate Approved Phase 4 3344-18-1
48
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
49
Ustekinumab Approved, Investigational Phase 4 815610-63-0
50
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816

Interventional clinical trials:

(show top 50) (show all 2869)
# Name Status NCT ID Phase Drugs
1 An Open Label, Multi Center, Post Marketing Study Of Pain And Quality Of Life Outcomes In Subjects With a Single Painful Venous Leg Ulcer Treated With Apligraf® Unknown status NCT02011724 Phase 4
2 Helicobacter Pylori Eradication Therapy on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection of Gastric Neoplastic Lesions: a Multicenter, Randomized, Double Blind, and Placebo Controlled Trial Unknown status NCT00926809 Phase 4 Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin;Lansoprazole (proton pump inhibitor), placebo
3 Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori Unknown status NCT01922765 Phase 4 amoxicillin, clarithromycin, metronidazole, rabeprazole
4 Phase IV Study Comparing Helicobacter Pylori Empiric Eradication With Test-Guided Treatment in Patients With Peptic Ulcer Bleeding Unknown status NCT00687336 Phase 4
5 Efficacy of an Ecabet Sodium and Proton Pump Inhibitor (PPI) Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection: A Prospective Randomized Controlled Trial Unknown status NCT01308177 Phase 4 Ecabet
6 A Prospective Single Blind Randomised Controlled Study to Compare the Outcomes of Patients With Diabetes and Clinically Non-infected Neuro-ischaemic and Neuropathic Foot Ulcers Treated With and Without Oral Antibiotics. Unknown status NCT01418456 Phase 4 antibiotics
7 A Controlled Clinical Trial of Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers Unknown status NCT02742233 Phase 4 saxagliptin;placebo
8 Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer. Unknown status NCT02638584 Phase 4 Ilaprazole;Rabeprazole
9 Post-Market Clinical Evaluation of the Spiracur SNaP Wound Care System Unknown status NCT01113658 Phase 4
10 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
11 Compare Gastric Acid Suppression of Esomeprazole by Oral or Intravenous Administration - A Randomized Trial Unknown status NCT00471029 Phase 4 esomeprazole
12 Olive Oil's Cream Effectiveness in Prevention of Pressure Ulcers in Immobilized Patients in Primary Care.A Cluster Randomized Clinical Trial. Unknown status NCT01595347 Phase 4 Hyper-oxigenated fatty acid
13 A Comparison of Total Contact Casting (TCC-EZ) Using Human Amnion Allograft (AmnioExcel) Versus Total Contact Casting (TCC-EZ) and Standard Wound Care in Treating Diabetic Foot Ulcers (TAD) Unknown status NCT02344329 Phase 4
14 PREDICT UC: Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis - A Randomised Controlled Trial Unknown status NCT02770040 Phase 4 Infliximab
15 A 12-week, Single Site, Randomized Controlled Trial to Compare the Efficacy of Quantum NPWT With and Without Simultaneous Irrigation Versus Standard of Care on Reduction of the Volume of Stage III/IV Pressure Ulcers. Unknown status NCT01734109 Phase 4
16 Phase IV Prospective, Multi-Center, Randomized, Single-Blind, Active and Standard Care-Controlled Study of DermaPure™ in Patients With "Hard to Heal" Chronic, Neuropathic Diabetic Foot Ulcers With Crossover Design for Standard Care Arm Unknown status NCT02081352 Phase 4
17 The Effect of Insulin Infusion on Metabolic Control and Inflammation in Diabetic Patients During Cardio-vascular Intervention and/or Treatment for Acute Foot Ulcer Infection. Unknown status NCT00700154 Phase 4
18 Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis: An Open-label,Randomized,Phase IV Clinical Trial Unknown status NCT02962245 Phase 4 berberine;regular treatment
19 Comparison of the Efficacy of Sequential Therapy and Bismuth Quadruple Therapy in the First Line and Second Line Therapy for Helicobacter Pylori Infection- A Multi-center Randomized Trial Unknown status NCT03156855 Phase 4 14-day sequential therapy;Bismuth quadruple therapy
20 Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
21 Banding Ligation With Carvedilol vs. Carvedilol for the Prevention of First Bleeding in Cirrhotics With Moderate Varices Unknown status NCT01383044 Phase 4 carvedilol
22 Esomeprazole or Famotidine in the Management of Aspirin Related Non-ulcer Dyspepsia - a Double Blind Randomized Control Study Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
23 A Double Blind Study Comparing Low Dose and High Dose IV Esomeprazole After Successful Endoscopic Therapy in Patients With Peptic Ulcer Bleeding Unknown status NCT01275937 Phase 4 Esomeprazole;esomeprazole
24 Maggot Debridement Therapy Versus Conventional Dressing Therapy to Treat Type 2 Diabetic Mellitus Foot Ulcers: A Prospective Randomized Controlled Study Unknown status NCT02816749 Phase 4
25 Effectiveness Comparison Between the Use of Skin Micro-grafts vs Meshed Split Thickness Skin Grafts in Cutaneous Defects: A Randomized Controlled Clinical Trial Unknown status NCT02813213 Phase 4
26 Pilot Study to Evaluate the Efficacy of Golimumab for Induction and Maintenance of Clinical and Endoscopic Remission in Patients With Steroid-dependent Ulcerative Colitis Unknown status NCT02412085 Phase 4 Golimumab
27 Aspirin and the Antiproteinuric Effect of Enalapril in Microalbuminuric Type 2 Diabetes Mellitus Patients: a Randomized, Double-Blind, Placebo-Controlled Study Unknown status NCT00427271 Phase 4 aspirin
28 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
29 Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
30 Comparison Between Two Therapeutic Strategies for the Maintenance of Clinical and Endoscopic Remission in Patients With Ulcerative Colitis Treated by Infliximab Unknown status NCT03151525 Phase 4 Azathioprine;Infliximab
31 A Randomized, Double-blind Study Investigating the Efficacy and Safety of Mesalazine With Hydrocortisone Sodium Succinate (100mg QD) Enema for 4-Week Treatment in Patients With Ulcerative Colitis (UC) Unknown status NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
32 Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis. Unknown status NCT01941589 Phase 4 oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone;corticosteroids only
33 A Prospective Open-label Study on Efficacy and Tolerability of Colloidal Bismuth Sub-citrate as Adjunctive Therapy to a Combination of Esomeprazole, Amoxicillin and Metronidazole for 10 Days for Helicobacter Pylori Elimination in Children Unknown status NCT03299725 Phase 4 colloidal bismuth sub-citrate
34 The Safety, Efficacy and Convenience of Use of the Natural Agent "Superlysin Gel" as Treatment for Herpes Labialis in Comparison to Acyclovir 5% and Docozanole 10%. Unknown status NCT00467662 Phase 4 Acyclovir 5%;Docosanol 10%
35 Prevention of Esophageal Variceal Rebleeding Unknown status NCT00863837 Phase 4 terlipressin (vasoconstrictor);pantoloc (proton pump inhibitor)
36 Probiotic for the Restoration of Intestinal Permeability and Reduction of Intestinal Inflammation in Active Ulcerative Colitis: A Double Blind Randomized Placebo Controlled Trial Unknown status NCT01479660 Phase 4 Probiotic
37 Personalised Medicine: a Break Through Approach for Early Determination of Anti Tumor Necrosis Factor (TNF) Responders and Non Responders Among Patients With Ulcerative Colitis in a Prospective Study With Golimumab (Simponi) Unknown status NCT02186886 Phase 4 Golimumab
38 Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple "Hybrid" and "Concomitant" Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
39 "Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" Unknown status NCT02028234 Phase 4 Pantoprazole,;Omeprazole
40 Randomized Controlled Trial Comparing the Efficacy of Polyethylene Glycol Alone and Polyethylene Glycol Combined With Topical Diltiazem in Treating Anal fissure in Children Unknown status NCT02419534 Phase 4 Polyethylene glycol;Polyethylene glycol with Diltiazem
41 Comparison of Triple Therapy Regimens Effectiveness Over 10 Days and 14 Days in Eradication of Helicobacter Pylori Infection: Double Blind Randomized Clinical Trial Unknown status NCT03134378 Phase 4 Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg
42 Comparison of the Efficacy of Triple Therapy With or Without Acetylcysteine in the First Line of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
43 Optimal Anti-Platelet Treatment for Patients With Stent IMplantation And Clopidogrel Low Response: OPTIMAL Study Unknown status NCT01955200 Phase 4 Ticagrelor;Clopidogrel;Cilostazol;Clopidogrel;Clopidogrel
44 The Impact of Early Feeding Following Ligation of the Acute Bleeding Varices Unknown status NCT01287702 Phase 4
45 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
46 Comparative Study of Antiemetic Effect of Ramosetron With Combination of Ondansetron and Dexamethasone in Patients Undergoing Laparoscopic Cholecystectomy Unknown status NCT02803788 Phase 4 ramosetron, ondansetron, dexamethasone
47 Prospective, Randomized Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Plus Epinephrine Injection in Nonvariceal Upper Gastrointestinal Bleeding Unknown status NCT02537353 Phase 4 Hemospray;Adrenaline
48 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
49 Comparison of the Incidence of Ventilator Associated Pneumonia in Patients Intubated With the Taper Guard Endotracheal Tube Versus a Normal Endotracheal Tube Unknown status NCT01501227 Phase 4
50 A Post-Marketing Clinical Study of Rebamipide to Investigate the Gastric Ulcer Healing Effect of Continued Dosing Following Helicobacter Pylori Eradication Therapy Completed NCT00233389 Phase 4 Rebamipide

Search NIH Clinical Center for Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets

Cochrane evidence based reviews: ulcer

Sources

Genetic Tests for Gastrointestinal Ulceration, Recurrent, with Dysfunctional...

About this section

Genetic tests related to Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets:

# Genetic test Affiliating Genes
1 Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets 29 PLA2G4A
Sources

Anatomical Context for Gastrointestinal Ulceration, Recurrent, with Dysfunctional...

About this section

MalaCards organs/tissues related to Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets:

40
Skin, Testes, Colon, Liver, Bone, Spinal Cord, Small Intestine
Sources

Publications for Gastrointestinal Ulceration, Recurrent, with Dysfunctional...

About this section

Articles related to Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets:

(show top 50) (show all 30323)
# Title Authors PMID Year
1
Bleeding diathesis and gastro-duodenal ulcers in inherited cytosolic phospholipase-A2 alpha deficiency. 6 56
25102815 2014
2
Cryptogenic multifocal ulcerating stenosing enteritis associated with homozygous deletion mutations in cytosolic phospholipase A2-α. 56 6
23268370 2014
3
Inherited human cPLA(2alpha) deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction. 56 6
18451993 2008
4
DNA methylation patterns of ulcer-healing genes associated with the normal gastric mucosa of gastric cancers. 61 54
20191040 2010
5
[Effect of yiqi huoxue formula on healing quality and recurrence rate of peptic ulcer]. 54 61
20214327 2009
6
vacA genotypes in Helicobacter pylori strains isolated from patients with and without duodenal ulcer in Bahrain. 54 61
20107966 2009
7
Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. 54 61
19638336 2009
8
[Effect of transcranial electrostimulation on clinical and laboratory characteristics in patients with gastric ulcer]. 54 61
19708562 2009
9
[Six cases with Behcet's disease presenting cervical ulcer]. 61 54
19570421 2009
10
Effect of genital ulcer disease on HIV-1 coreceptor expression in the female genital tract. 61 54
18008231 2007
11
[Comparison of the burn wound and diabetic ulcer wound]. 54 61
18396758 2007
12
[Genetic polymorphism of COX-1 gene and NSAID-induced ulcer]. 61 54
17926541 2007
13
The use of recombinant human epidermal growth factor to promote healing for chronic radiation ulcer. 61 54
17924878 2007
14
[Clinical study on effect of Jianwei Yuyang Granule in treating patients with gastric ulcer]. 61 54
17717918 2007
15
Helicobacter pylori cagA and iceA genotypes status and risk of peptic ulcer in Saudi patients. 54 61
17334464 2007
16
Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. 54 61
17258718 2007
17
Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks. 54 61
17008926 2006
18
Regulated spatial distribution of cyclooxygenases and lipoxygenases in Crohn's ulcer. 54 61
16951496 2006
19
Recent advances in gastric ulcer therapeutics. 54 61
16188503 2005
20
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. 54 61
16271912 2005
21
Cellular and molecular mechanisms of gastrointestinal ulcer healing. 61 54
16184417 2005
22
Prostaglandins and ulcer healing. 61 54
16247187 2005
23
An overview of acetic acid ulcer models--the history and state of the art of peptic ulcer research. 54 61
16079471 2005
24
Correlation of the Helicobacter pylori adherence factor BabA with duodenal ulcer disease in four European countries. 61 54
15866209 2005
25
Keratinocyte and dermal vascular endothelial cell capacities remain unimpaired in the margin of chronic venous ulcer. 61 54
15565301 2005
26
Distribution of vacA alleles and cagA status of Helicobacter pylori in peptic ulcer disease and non-ulcer dyspepsia. 61 54
15606640 2004
27
Three cases of ischemic ulcer due to arteriosclerosis obliterans responding to basic fibroblast growth factor spray. 61 54
15372302 2004
28
Serum response factor promotes re-epithelialization and muscular structure restoration during gastric ulcer healing. 61 54
15188176 2004
29
[Are COX-2 inhibitors truly able to prevent NSAIDs-associated ulcer?]. 61 54
15038104 2004
30
Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs? 61 54
14998430 2004
31
Biphasic role of platelet-activating factor in oral mucosal ulcer healing. 54 61
14609204 2003
32
Serum positive cagA in patients with non-ulcer dyspepsia and peptic ulcer disease from two centers in different regions of Turkey. 61 54
12679943 2003
33
A therapy-resistant chronic leg ulcer treated successfully with topical basic fibroblast growth factor. 54 61
12760319 2003
34
Effect of rebamipide on acetic acid-induced gastric ulcer in rats: involvement of hepatocyte growth factor. 61 54
12678329 2003
35
cagA and vacA in strains of Helicobacter pylori from ulcer and non-ulcerative dyspepsia patients. 54 61
12223115 2002
36
Antiangiogenic effect of a highly selective cyclooxygenase-2 inhibitor on gastric ulcer healing in rats. 54 61
12217640 2002
37
Esophageal ulceration activates keratinocyte growth factor and its receptor in rats: implications for ulcer healing. 61 54
11832460 2002
38
Overexpression of co-stimulatory molecules in peripheral mononuclear cells of Helicobacter pylori-positive peptic ulcer patients: possible difference in host responsiveness compared with non-ulcer patients. 61 54
11204803 2001
39
Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. 54 61
10925968 2000
40
Growth factors in ulcer healing: lessons from recent studies. 61 54
10791686 2000
41
The role of gastrin in ulcer pathogenesis. 61 54
10749086 2000
42
[Acid-base balance in ulcer patients]. 61 54
10881506 2000
43
Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding. 54 61
10597118 1999
44
Helicobacter pylori cagA status, vacA genotypes and ulcer disease. 61 54
9619383 1998
45
Does CagA contribute to ulcer pathogenesis in a developing country, such as Sudan? 61 54
9855047 1998
46
Changes in mucosal levels of transforming growth factor-alpha from the oxyntic region and ulcer site during duodenal ulcer healing with ranitidine or sucralfate. 61 54
9602986 1998
47
Epidermal growth factor and transforming growth factor alpha in duodenal ulcer and non-ulcer dyspepsia patients before and after Helicobacter pylori eradication. 61 54
9517524 1998
48
[Gastrin and its role in the development of ulcer disease]. 61 54
9198884 1997
49
Il-2 receptor expression on gastric mucosa T lymphocytes is enhanced in duodenal ulcer patients compared with non-ulcer dyspeptic patients. 61 54
8975986 1996
50
Serum CagA antibodies in asymptomatic subjects and patients with peptic ulcer: lack of correlation of IgG antibody in patients with peptic ulcer or asymptomatic Helicobacter pylori gastritis. 61 54
8943750 1996
Sources

Variations for Gastrointestinal Ulceration, Recurrent, with Dysfunctional...

About this section

ClinVar genetic disease variations for Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PLA2G4A NM_024420.2(PLA2G4A):c.1723G>C (p.Asp575His)SNV Pathogenic 624621 rs1557895416 1:186934684-186934684 1:186965552-186965552
2 PLA2G4A NM_024420.2(PLA2G4A):c.2118+4_2118+7deldeletion Pathogenic 624622 rs1557901999 1:186948605-186948608 1:186979473-186979476
3 PLA2G4A NM_001311193.2(PLA2G4A):c.378+17114dupduplication Pathogenic 807464 1:186880456-186880457 1:186911324-186911325
4 PLA2G4A NM_024420.2(PLA2G4A):c.331T>C (p.Ser111Pro)SNV Pathogenic 9079 rs121434634 1:186863296-186863296 1:186894164-186894164
5 PLA2G4A NM_024420.2(PLA2G4A):c.1454G>A (p.Arg485His)SNV Pathogenic 9080 rs121434635 1:186925351-186925351 1:186956219-186956219

UniProtKB/Swiss-Prot genetic disease variations for Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets:

73
# Symbol AA change Variation ID SNP ID
1 PLA2G4A p.Asp575His VAR_082091

Sources

Expression for Gastrointestinal Ulceration, Recurrent, with Dysfunctional...

About this section
Search GEO for disease gene expression data for Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets.
Sources

Pathways for Gastrointestinal Ulceration, Recurrent, with Dysfunctional...

About this section

Pathways related to Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Phospholipase-C Pathway 63
Show member pathways
 12.85 PLA2G4A PDGFB FGF2 EGF
2
p70S6K Signaling 63
Show member pathways
 12.83 PTGS2 PDGFB FGF2 EGF
3
DAG and IP3 signaling 65
Show member pathways
 12.77 PTGS2 PTGS1 PLA2G4A PDGFB EGF
4
PI3K-Akt signaling pathway 36
Show member pathways
 12.76 PTGS2 PDGFB FGF2 EGF
5
Pathways in cancer 36
12.61 PTGS2 PDGFB FGF2 EGF
6
MAPK signaling pathway 36 1
12.52 PLA2G4A PDGFB FGF2 EGF
7
Ras signaling pathway 36
Show member pathways
 12.47 PLA2G4A PDGFB FGF2 EGF
8
Phospholipase D signaling pathway 36
Show member pathways
 12.21 PLA2G4A PDGFB EGF
9
VEGF Pathway (Qiagen) 63
Show member pathways
 12.2 PLA2G4A GAST EGF
10
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.2 PTGS2 PTGS1 PLA2G4A
11
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.12 PTGS2 HRH2 EGF
12
Arachidonic acid metabolism 65
Show member pathways
 11.98 PTGS2 PTGS1 PLA2G4A
13
Development EGFR signaling via small GTPases 22
Show member pathways
 11.92 PLA2G4A PDGFB EGF
14
Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers 64
11.84 PDGFB FGF2 EGF
15
Linoleic acid metabolism 36
Show member pathways
 11.75 PTGS2 PTGS1 PLA2G4A
16
Serotonergic synapse 36
11.73 PTGS2 PTGS1 PLA2G4A
17
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.63 PDGFB FGF2 EGF
18
Neural Stem Cells and Lineage-specific Markers 64
11.51 PDGFB FGF2 EGF
19
Platelet Aggregation Inhibitor Pathway, Pharmacodynamics 60
11.37 PTGS1 PLA2G4A
20
Ovarian steroidogenesis 36
11.37 PTGS2 PLA2G4A
21
Lung fibrosis 1
11.34 PDGFB FGF2 EGF
22
Celecoxib Pathway, Pharmacodynamics 60
11.26 PTGS2 PTGS1 PLA2G4A
23
Signaling mediated by p38-alpha and p38-beta 1
11.18 PTGS2 PLA2G4A
24
Differentiation Pathway 1
11.11 PDGFB FGF2 EGF
25
HETE and HPETE biosynthesis and metabolism 22
Show member pathways
 11.05 PTGS2 PTGS1
26
Eicosanoid Synthesis 1
10.99 PTGS2 PTGS1
27
Angiogenesis (WikiPathways) 1
10.99 PDGFB FGF2
28
Vemurafenib Pathway, Pharmacodynamics 60
10.97 PDGFB FGF2 EGF
29
Prostaglandin 2 biosynthesis and metabolism FM 22
10.96 PTGS2 PTGS1
30
Overview of nanoparticle effects 1
10.85 PTGS2 PTGS1
31
Etoposide Pathway, Pharmacokinetics/Pharmacodynamics 60
10.73 PTGS2 PTGS1
32
Prostaglandin Synthesis and Regulation 1
10.61 PTGS2 PTGS1 PLA2G4A
33
Ibuprofen Pathway, Pharmacodynamics 60
10.25 PTGS2 PTGS1 PLA2G4A
34
Secretion of Hydrochloric Acid in Parietal Cells 1
10.1 HRH2 GAST
Sources

GO Terms for Gastrointestinal Ulceration, Recurrent, with Dysfunctional...

About this section

Biological processes related to Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.76 PDGFB FGF2 EGF
2 angiogenesis GO:0001525 9.73 PTGS2 FGF2 EGF
3 positive regulation of cell proliferation GO:0008284 9.73 PTGS2 PDGFB FGF2 EGF
4 regulation of cell proliferation GO:0042127 9.69 PTGS2 PTGS1 PLA2G4A
5 positive regulation of protein kinase B signaling GO:0051897 9.63 PDGFB FGF2 EGF
6 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.61 PDGFB FGF2
7 positive chemotaxis GO:0050918 9.61 PDGFB FGF2
8 positive regulation of blood vessel endothelial cell migration GO:0043536 9.6 PDGFB FGF2
9 positive regulation of cell division GO:0051781 9.59 PDGFB FGF2
10 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.58 PDGFB FGF2
11 positive regulation of protein tyrosine kinase activity GO:0061098 9.57 PDGFB EGF
12 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.55 PTGS2 FGF2
13 positive regulation of vasoconstriction GO:0045907 9.54 PTGS2 HRH2
14 positive regulation of MAPK cascade GO:0043410 9.54 PDGFB FGF2 EGF
15 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.52 PDGFB FGF2
16 positive regulation of mitotic nuclear division GO:0045840 9.49 PDGFB EGF
17 prostaglandin metabolic process GO:0006693 9.48 PTGS2 PTGS1
18 positive regulation of DNA biosynthetic process GO:2000573 9.4 PDGFB FGF2
19 positive regulation of MAP kinase activity GO:0043406 9.33 PDGFB FGF2 EGF
20 cyclooxygenase pathway GO:0019371 9.32 PTGS2 PTGS1
21 paracrine signaling GO:0038001 9.26 PDGFB FGF2
22 positive regulation of hyaluronan biosynthetic process GO:1900127 8.96 PDGFB EGF
23 prostaglandin biosynthetic process GO:0001516 8.8 PTGS2 PTGS1 PLA2G4A

Molecular functions related to Gastrointestinal Ulceration, Recurrent, with Dysfunctional Platelets according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemoattractant activity GO:0042056 9.26 PDGFB FGF2
2 peroxidase activity GO:0004601 9.16 PTGS2 PTGS1
3 growth factor activity GO:0008083 9.13 PDGFB FGF2 EGF
4 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS2 PTGS1
Sources

Sources for Gastrointestinal Ulceration, Recurrent, with Dysfunctional...

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....